VARIPULSE Catheter for Atrial Fibrillation

(SPAA PFA Trial)

This trial evaluates the safety and effectiveness of the VARIPULSE catheter system for treating persistent atrial fibrillation (PsAF), a heart rhythm disorder. It focuses on catheter ablation, a procedure that isolates certain heart veins to restore normal rhythm. Some participants will also undergo a procedure to reduce stroke risk. Ideal candidates have been diagnosed with persistent atrial fibrillation for more than a week but less than a year and have not received previous ablation treatment. As an unphased trial, this study allows patients to contribute to innovative research and potentially benefit from cutting-edge treatment options.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that the VARIPULSE Catheter System is generally safe. In one study, only 0.4% of patients experienced complications during the procedure. Another study found no major side effects, with the treatment proving effective for 80% of patients over a year. This indicates that most patients did not experience serious side effects, and the treatment was successful for them. A different study also reported a low rate of primary side effects, just 0.6%, with no strokes or serious issues related to the procedure.

Researchers are excited about the VARIPULSE Catheter System because it offers a unique approach to treating persistent atrial fibrillation (PsAF). Unlike standard treatments like antiarrhythmic drugs or traditional catheter ablation that mainly focus on pulmonary vein isolation (PVI), VARIPULSE includes superior vena cava isolation (SVCI) and optional posterior wall isolation (PWI), aiming to enhance the effectiveness of the procedure. This comprehensive targeting could improve outcomes by addressing multiple potential sources of arrhythmia. Additionally, the potential for incorporating a left atrial appendage occlusion (LAAO) procedure is a promising feature that could reduce the risk of stroke, a common concern in atrial fibrillation patients. Overall, these features make VARIPULSE a potentially more holistic and effective treatment option for PsAF.

Research has shown that the VARIPULSE catheter system effectively treats atrial fibrillation (AF), a type of irregular heartbeat. One study reported that 87.7% of patients did not experience irregular heartbeats after one year. Another study found it to be 75% effective over 12 months, with effectiveness peaking at 85%. The system also demonstrated a 99.7% success rate immediately after treatment. Additionally, it maintains a strong safety record, with very few complications reported. In this trial, participants will undergo catheter ablation using the VARIPULSE Catheter System, with some receiving additional procedures such as posterior wall isolation (PWI) or left atrial appendage occlusion (LAAO). These findings suggest that the VARIPULSE catheter system could be a promising option for managing persistent atrial fibrillation.¹⁶⁷⁸⁹